Jennifer Gansert

9.0k total citations · 4 hit papers
31 papers, 4.5k citations indexed

About

Jennifer Gansert is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jennifer Gansert has authored 31 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Jennifer Gansert's work include Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Treatment and Pharmacology (6 papers). Jennifer Gansert is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Treatment and Pharmacology (6 papers). Jennifer Gansert collaborates with scholars based in United States, Spain and Australia. Jennifer Gansert's co-authors include Kelly S. Oliner, Lisa Chen, Igor Puzanov, Robert H.I. Andtbacka, Josep Tabernero, Jean‐Yves Douillard, David Cunningham, Salvatore Siena, Mario Barugel and Ronald L. Burkes and has published in prestigious journals such as Cell, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Jennifer Gansert

30 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

2010 1.4k citations Jean‐Yves Douillard, Salvatore Siena et al. Journal of Clinical Oncology profile →
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Antoni Ribas, Reinhard Dummer et al. Cell profile →
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

2010 755 citations Marc Peeters, Timothy Price et al. Journal of Clinical Oncology profile →
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

2017 471 citations Jason Chesney, Igor Puzanov et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jennifer Gansert

Since Specialization

Citations

This map shows the geographic impact of Jennifer Gansert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Gansert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Gansert more than expected).

Fields of papers citing papers by Jennifer Gansert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Gansert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Gansert. The network helps show where Jennifer Gansert may publish in the future.

Co-authorship network of co-authors of Jennifer Gansert

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Gansert. A scholar is included among the top collaborators of Jennifer Gansert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Gansert. Jennifer Gansert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy breakdown → 2017 ·Cell ·Antoni Ribas, Reinhard Dummer, Igor Puzanov, Ari M. Vanderwalde, Robert H.I. Andtbacka, Olivier Michielin, Anthony J. Olszanski, Josep Malvehy, Jonathan Cebon, Eugenio Fernández, John M. Kirkwood, Thomas F. Gajewski, Lisa Chen, Kevin Gorski, Abraham Anderson, Scott J. Diede, Michael E. Lassman, Jennifer Gansert, F. Stephen Hodi, Georgina V. Long	1142
2	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma breakdown → 2017 ·Journal of Clinical Oncology ·Jason Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed Milhem, John A. Glaspy, Omid Hamid, Merrick I. Ross, Philip Friedlander, Claus Garbe, Theodore F. Logan, Axel Hauschild, Célèste Lebbé, Lisa Chen, Jaeyeon Kim, Jennifer Gansert, Robert H.I. Andtbacka, Howard L. Kaufman	471
3	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer 2014 ·Clinical Cancer Research ·Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Joe Stephenson, Élena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero	92
4	Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study 2014 ·Japanese Journal of Clinical Oncology ·Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Yoshikazu Kobayashi, (unknown), (unknown), Jennifer Gansert	12
5	Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. 2014 ·Journal of Clinical Oncology ·Howard L. Kaufman, Robert Hans Ingemar Andtbacka, Frances A. Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A. Delman, Lynn E. S̄pitler, Igor Puzanov, Yining Ye, Li Ai, Jennifer Gansert, Robert S. Coffin, Merrick I. Ross	36
6	Patterns of durable response with intralesional talimogene laherparepvec (T-VEC): Results from a phase III trial in patients with stage IIIb-IV melanoma. 2014 ·Journal of Clinical Oncology ·Merrick I. Ross, Robert Hans Ingemar Andtbacka, Igor Puzanov, Mohammed Milhem, Frances A. Collichio, Keith A. Delman, R. Dirk Noyes, Jonathan S. Zager, Lee D. Cranmer, Lynn E. S̄pitler, Eddy C. Hsueh, David W. Ollila, Thomas Amatruda, Lisa Chen, Jennifer Gansert, Howard L. Kaufman	5
7	Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor 2013 ·Clinical Cancer Research ·Ian McCaffery, Yanyan Tudor, Hongjie Deng, Rui Tang, Samuel Suzuki, Sunita Badola, Hedy L. Kindler, Charles S. Fuchs, Elwyn Loh, Scott D. Patterson, Li Chen, Jennifer Gansert	54
8	A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 2 STUDY OF GANITUMAB OR RILOTUMUMAB WITH PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (SCLC) 2013 ·Journal of Thoracic Oncology ·Bonnie S. Glisson, Andrzej Każarnowicz, Kristiaan Nackaerts, Sergey Orlov, Rodryg Ramlau, Benjamin Besse, Manuel Cobo, Hari Menon, Luis Paz-Ares Rodríguez, Yilong Zhang, Min Zhu, Yizhou Jiang, Elwyn Loh, Jennifer Gansert, Sarita Dubey	4
9	Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial 2013 ·The Lancet Oncology ·J.F.R. Robertson, Jean-Marc Ferrero, Hugues Bourgeois, Hagen F. Kennecke, Richard H. De Boer, William Jacot, Jesse McGreivy, Samuel Suzuki, Min Zhu, Ian McCaffery, Elwyn Loh, Jennifer Gansert, Peter A. Kaufman	137
10	Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G). 2011 ·Journal of Clinical Oncology ·Ian McCaffery, Yanyan Tudor, Hepu Deng, (unknown), Sunita Badola, Hedy L. Kindler, Christiane Fuchs, Elwyn Loh, Scott D. Patterson, (unknown), Jennifer Gansert	6
11	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study breakdown → 2010 ·Journal of Clinical Oncology ·Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy, Josep Tabernero, Ronald L. Burkes, Mario Barugel, Yves Humblet, G. Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean‐Luc Canon, M. Rother, Kelly S. Oliner, Michael Wolf, Jennifer Gansert	1351
12	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer breakdown → 2010 ·Journal of Clinical Oncology ·Marc Peeters, Timothy Price, Andrés Cervantes, Alberto Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Valentina Tzekova, Simon Collins, Kelly S. Oliner, Alan Rong, Jennifer Gansert	755
13	Prime study : a randomised phase 3 study of panitumumab with Folfox4 versus Folfox4 alone as first line treatment for metastatic colorectal cancer (mCRC) 2010 ·Annals of Oncology ·Salvatore Siena, Jean‐Yves Douillard, (unknown), James T. Cassidy, Ronald L. Burkes, Mario Barugel, Yves Humblet, David Cunningham, Michael Wolf, Jennifer Gansert	1
14	Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). 2010 ·Journal of Clinical Oncology ·Jean‐Yves Douillard, J Cassidy, Jacek Jassem, Fernando Rivera, Ilona Kocáková, Wolf Rogowski, J. R. Canon, (unknown), Feng Xu, Jennifer Gansert	14
15	Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining. 2010 ·Journal of Clinical Oncology ·Marc Peeters, Andrés Cervantes, A. H. Strickland, T-E. Ciuleanu, Paul N. Mainwaring, Valentina Tzekova, Armando Santoro, (unknown), (unknown), Jennifer Gansert	11
16	KRAS Mutational Status as a Predictor of Epidermal Growth Factor Receptor Inhibitor Efficacy in Colorectal Cancer 2009 ·American Journal of Therapeutics ·Roy D. Baynes, Jennifer Gansert	21
17	8514 SPECTRUM, a phase III trial for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab: interim pooled safety analysis 2009 ·European Journal of Cancer Supplements ·(unknown), Ірина Давиденко, Eric Winquist, Lisa Licitra, Krzysztof Składowski, T-E. Ciuleanu, Rakesh Kumar, P. Foa, Jennifer Gansert, Jan B. Vermorken	0
18	10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial 2009 ·European Journal of Cancer Supplements ·Jean‐Yves Douillard, Salvatore Siena, (unknown), Josep Tabernero, Ronald L. Burkes, Mario Barugel, Y. Humblet, David Cunningham, M. Wolf, Jennifer Gansert	63
19	Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC) 2009 ·Journal of Clinical Oncology ·Timothy Price, Marc Peeters, Jean‐Yves Douillard, E. Mitchell, Allen Lee Cohn, A. H. Strickland, Fernando Rivera, Feng Xu, Jennifer Gansert, Salvatore Siena	3
20	Human NKT Cells Express Granulysin and Exhibit Antimycobacterial Activity 2003 ·The Journal of Immunology ·Jennifer Gansert, (unknown), (unknown), Frederick Wittke, Martin Röllinghoff, Alan M. Krensky, Steven A. Porcelli, Robert L. Modlin, Steffen Stenger	148

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact